news

CDMO delivers 4,000 doses of COVID-19 vaccine candidate for Phase II/III trial

27
SHARES

Advent announced it has manufactured and delivered the first 4,000 doses of the AZD1222 vaccine candidate for the University of Oxford clinical trial.

vial labelled 'COVID-19 Vaccine'

Advent, an Italian Contract Manufacturing Organization (CMO) has manufactured and delivered the first batch of ChAdOx1 nCoV-19 (now called AZD1222), a novel COVID-19 vaccine candidate, for Phase II/III clinical trial.

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

The COV002 trial is being undertaken by the University of Oxford, UK. The first batch included 4,000 doses of the vaccine.

The AZD1222 vaccine uses a non-replicating adenovirus vector with the addition of the SARS-CoV-2 Spike (S) protein. SARS-CoV-2 is the virus causing the COVID-19 pandemic.

According to the CMO, it manufactured the first batch of vaccine in just over a month from receiving the seed stock. This was done by rapidly devising a manufacturing process to produce 13,000 doses of the COVID-19 vaccine. The company said the rapid and reliable development of a large-scale manufacturing process was critical, as Phase I trials are already underway.

“Speed is of the essence when facing a new outbreak such as this unprecedented Covid-19 pandemic,” said Professor Sarah Gilbert of the University of Oxford’s Jenner Institute. “Advent has manufactured and delivered the vaccine very quickly, producing a clinical batch in just over one month since we provided the seed stock, enabling us to rapidly prepare for larger scale clinical trials.”

The University of Oxford is partnering with AstraZeneca for the development and potential large-scale distribution of the vaccine candidate.

Share via
Share via